HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2014.
Quarter ended March 31, 2014 Highlights - compared to March 31, 2013
- Net sales of $187.2 million, increased $22.0 million, or 13.3%, with a slight decrease in volumes
- Gross profit, as a percentage of net sales was 75.5%, compared to 72.4%
- Research and development expenses increased 7.9% to $13.2 million, however as a percentage of net sales decreased from 7.4% to 7.0%
- Selling, marketing, general and administrative expenses, as a percentage of net sales, was 14.2% compared to 13.4%
- Operating income increased to $101.5 million, or 54.3% of net sales, compared to $63.1 million, or 38.2% of net sales
- Net income attributable to Taro was $89.6 million compared to $49.2 million, resulting in diluted earnings per share of $2.10 (which reflects 1,959,514 less shares due to the impact from the December 2013 tender offer) compared to $1.10
Year ended March 31, 2014 Highlights - compared to March 31, 2013
- Net sales of $759.3 million, increased $88.3 million, or 13.2%, with a slight decrease in volumes
- Gross profit, as a percentage of net sales was 76.4%, compared to 73.7%
- Research and development expenses increased 19.2% to $55.4 million or 7.3% of net sales compared to 6.9%
- Selling, marketing, general and administrative expenses increased $5.3 million, however, as a percentage of net sales decreased to 12.1% from 12.9%
- Settlements and loss contingencies of $2.6 million compared to $33.3 million in 2013, related to certain price reporting litigations
- Operating income increased to $430.3 million, or 56.7% of net sales, compared to $328.6 million, or 49.0% of net sales
- Net income attributable to Taro was $360.4 million compared to $266.2 million, a $94.2 million increase, resulting in diluted earnings per share of $8.14 compared to $5.95
Cash Flow and Balance Sheet Highlights
- Cash provided by operations for the year ended March 31, 2014 was $357.6 million, as compared to $248.7 million for the year ended March 31, 2013
- Cash at March 31, 2014 (including marketable securities), which includes the impact from the December 2013 tender offer of $193.0 million (which includes fees and expenses), increased $71.9 million to $632.4 million from March 31, 2013
FDA Approvals and Filings
The Company recently received approval from the U.S. Food and Drug Administration (“FDA”) for an Abbreviated New Drug Application (“ANDA”) for Phenytoin Chewable Tablets USP, 50 mg. During the quarter, the Company filed three ANDAs with the FDA. With this, ANDAs representing twenty-seven products await FDA approval, of which one is tentatively approved.
Taro Announces Results of its Extraordinary General Meeting of Shareholders
On March 27, 2014, Taro announced the Company held an extraordinary general meeting of shareholders for the purpose of the ratification of certain resolutions adopted by the Company’s shareholders at its 2013 annual general meeting. The resolutions that were approved and ratified were the following: (i) approval of the Company’s compensation policy, (ii) approval of compensation to three of its directors (Dilip Shanghvi, Sudhir Valia and Kal Sundaram), and (iii) re-election of its external directors (Ilana Avidov Mor and Dan Biran).
******
About Taro
Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.
SAFE HARBOR STATEMENT
The unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments necessary to present fairly the financial condition and results of operations of the Company. The unaudited consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 20-F, as filed with the SEC.
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements that do not describe historical facts or that refer or relate to events or circumstances the Company “estimates,” “believes,” or “expects” to happen or similar language, and statements with respect to the Company’s financial performance, availability of financial information, and estimates of financial results and information for fiscal year 2014. Although the Company believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurances that its expectations will be attained. Factors that could cause actual results to differ include general domestic and international economic conditions, industry and market conditions, changes in the Company's financial position, litigation brought by any party in any court in Israel, the United States, or any country in which Taro operates, regulatory and legislative actions in the countries in which Taro operates, and other risks detailed from time to time in the Company’s SEC reports, including its Annual Reports on Form 20-F. Forward-looking statements are applicable only as of the date on which they are made. The Company undertakes no obligations to update, change or revise any forward-looking statement, whether as a result of new information, additional or subsequent developments or otherwise.
**Financial Tables Follow**
|
TARO PHARMACEUTICAL INDUSTRIES LTD. |
||||||||||||
|
Quarter Ended |
Year Ended |
|||||||||||
|
2014 |
2013 | 2014 | 2013 | |||||||||
| (unaudited) | (unaudited) | (unaudited) | (audited) | |||||||||
| Sales, net | $187,176 | $ 165,133 | $ 759,285 | $ 670,954 | ||||||||
| Cost of sales | 45,818 | 45,658 | 179,279 | 176,128 | ||||||||
| Gross profit | 141,358 | 119,475 | 580,006 | 494,826 | ||||||||
|
Operating Expenses: |
||||||||||||
| Research and development | 13,167 | 12,202 | 55,430 | 46,508 | ||||||||
| Selling, marketing, general and administrative | 26,647 | 22,126 | 91,733 | 86,438 | ||||||||
| Settlements and loss contingencies | - | 22,000 | 2,590 | 33,300 | ||||||||
| Operating income | 101,544 | 63,147 | 430,253 | 328,580 | ||||||||
|
Financial Expenses, net: |
||||||||||||
| Interest and other financial (income) expenses, net | (1,241 | ) | (1,074 | ) | (5,167 | ) | (1,514 | ) | ||||
| Foreign exchange income | (3,897 | ) | (681 | ) | (7,118 | ) | (2,417 | ) | ||||
| Other income, net | 407 | 1,400 | 1,369 | 3,352 | ||||||||
| Income before income taxes | 107,089 | 66,302 | 443,907 | 335,863 | ||||||||
| Tax expense | 17,433 | 16,086 | 82,729 | 67,799 | ||||||||
| Income from continuing operations | 89,656 | 50,216 | 361,178 | 268,064 | ||||||||
| Net loss from discontinued operations | (97 | ) | (1,150 | ) | (319 | ) | (1,194 | ) | ||||
| Net income | 89,559 | 49,066 | 360,859 | 266,870 | ||||||||
| Net (loss) income attributable to non-controlling interest | (81 | ) | (101 | ) | 472 | 664 | ||||||
| Net income attributable to Taro | $ 89,640 | $ 49,167 | $ 360,387 | $ 266,206 | ||||||||
| Net income per ordinary share from continuing operations attributable to Taro: | ||||||||||||
| Basic | $ 2.10 | $ 1.13 | $ 8.15 | $ 5.99 | ||||||||
| Diluted | $ 2.10 | $ 1.13 | $ 8.15 | $ 5.98 | ||||||||
| Net loss per ordinary share from discontinued operations attributable to Taro: | ||||||||||||
| Basic | ($0.00)* | ($0.03 | ) | ($0.01 | ) | ($0.03 | ) | |||||
| Diluted | ($0.00)* | ($0.03 | ) | ($0.01 | ) | ($0.03 | ) | |||||
| Net income per ordinary share attributable to Taro: | ||||||||||||
| Basic | $ 2.10 | $ 1.10 | $ 8.14 | $ 5.96 | ||||||||
| Diluted | $ 2.10 | $ 1.10 | $ 8.14 | $ 5.95 | ||||||||
| Weighted-average number of shares used to compute net income per share: | ||||||||||||
| Basic | 42,830,989 | 44,757,257 | 44,276,003 | 44,677,603 | ||||||||
| Diluted | 42,832,772 | 44,762,748 | 44,279,124 | 44,715,111 | ||||||||
* Amount is less than $0.01.
May not foot due to rounding.
|
TARO PHARMACEUTICAL INDUSTRIES LTD. |
||||
|
March 31, |
March 31, |
|||
| 2014 | 2013 | |||
| (unaudited) | (audited) | |||
| ASSETS | ||||
| CURRENT ASSETS: | ||||
| Cash and cash equivalents | $ 209,967 | $ 237,284 | ||
| Short-term bank deposits | 418,946 | 312,603 | ||
| Restricted short-term bank deposits | 227 | 7,430 | ||
| Marketable securities | 3,255 | 3,183 | ||
|
Accounts receivable and other: |
||||
|
Trade, net |
138,772 |
119,810 |
||
| Other receivables and prepaid expenses | 162,392 | 119,768 | ||
| Inventories | 117,639 | 109,626 | ||
| Long-term assets held for sale, net | 73 | 67 | ||
| TOTAL CURRENT ASSETS | 1,051,271 | 909,771 | ||
| Long-term receivables and other assets | 52,894 | 23,227 | ||
| Property, plant and equipment, net | 151,416 | 145,265 | ||
| Other assets | 28,795 | 28,373 | ||
| TOTAL ASSETS | $ 1,284,376 | $ 1,106,636 | ||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||
| CURRENT LIABILITIES: | ||||
| Current maturities of long-term debt | $ 11,974 | $ 11,330 | ||
| Trade payables and other current liabilities | 241,330 | 181,201 | ||
| TOTAL CURRENT LIABILITIES | 253,304 | 192,531 | ||
| Long-term debt, net of current maturities | 5,888 | 17,269 | ||
| Deferred taxes and other long-term liabilities | 4,591 | 5,875 | ||
| TOTAL LIABILITIES | 263,783 | 215,675 | ||
| Taro shareholders’ equity | 1,015,507 | 886,347 | ||
| Non-controlling interest | 5,086 | 4,614 | ||
|
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY |
$ 1,284,376 | $ 1,106,636 | ||
|
TARO PHARMACEUTICAL INDUSTRIES LTD. |
||||||
|
|
||||||
|
Year Ended March 31, |
||||||
|
2014 |
2013 | |||||
| (unaudited) | (audited) | |||||
|
Operating Activities: |
||||||
| Net income | $360,859 | $266,870 | ||||
|
Adjustments required to reconcile net income to net cash provided by operating activities: |
||||||
| Depreciation and amortization | 16,567 | 17,765 | ||||
| Impairment of long-lived assets | 47 | 969 | ||||
| Share-based compensation expense | - | 8 | ||||
| Loss (gain) on sale of long-lived assets and marketable securities, net | 21 | (44 | ) | |||
| Increase in long-term debt due to currency fluctuations | 1,137 | 440 | ||||
| Increase in trade receivables, net | (19,755 | ) | (8,912 | ) | ||
| Change in derivative instruments, net | 4,181 | 1,550 | ||||
| Increase in other receivables, prepaid expenses and other assets | (43,106 | ) | (19,834 | ) | ||
| Increase in inventories, net | (10,697 | ) | (630 | ) | ||
| Effect of exchange differences on inter-company balances | (11,670 | ) | (1,510 | ) | ||
| Increase (decrease) in trade and other payables and liabilities | 60,060 | (8,022 | ) | |||
| Net cash provided by operating activities | 357,644 | 248,650 | ||||
|
|
||||||
| Investing Activities: | ||||||
| Purchase of property, plant & equipment | (21,249 | ) | (9,466 | ) | ||
| Investment in other intangible assets | (4,555 | ) | (777 | ) | ||
| Investment in long-term deposits and other assets | (33,956 | ) | (5,000 | ) | ||
| Investment in short-term bank deposits | (120,648 | ) | (241,671 | ) | ||
| Proceeds from restricted bank deposits | 7,203 | 8,224 | ||||
| (Investment in) proceeds from sale of marketable securities | (100 | ) | 4,758 | |||
| Proceeds from sale of long-lived assets | 8 | 1 | ||||
| Net cash used in investing activities | (173,297 | ) | (243,931 | ) | ||
| Financing Activities: | ||||||
| Purchase of treasury stock | (192,999 | ) | - | |||
| Excess tax benefits from share-based payment arrangements | 149 | 838 | ||||
| Proceeds from issuance of shares, net | 1,262 | 6,584 | ||||
| Repayments of long-term debt | (11,874 | ) | (10,748 | ) | ||
| Net cash used in financing activities | (203,462 | ) | (3,326 | ) | ||
| Effect of exchange rate changes | (8,202 | ) | (2,375 | ) | ||
| Net decrease in cash | (27,317 | ) | (982 | ) | ||
| Cash at beginning of period | 237,284 | 238,266 | ||||
| Cash at end of period | $209,967 | $237,284 | ||||
#####